PMID: 7525059Oct 1, 1994Paper

Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies

Cancer Immunology, Immunotherapy : CII
P RagnhammarH Mellstedt

Abstract

Unconjugated monoclonal antibodies (mAb) kill tumor cells in vivo by activating immune functions. One of these is ADCC (antibody-dependent cellular cytotoxicity). The efficacy of mAbs might be augmented if the cytotoxic capacity of the effector cells could be increased. In this study the augmenting effect of granulocyte-colony-stimulating factor (G-CSF), granulocyte/macrophage(GM)-CSF and macrophage(M)-CSF was analyzed. Effector cells [peripheral blood mononuclear cells (PBMC) or granulocytes] were activated for 4-6 h by the respective CSF and assayed in an 18-h Cr51-release assay. Human colorectal, lymphoma, glioma and melanoma cell lines were target cells. Mouse mAbs of different isotypes, as well as chimeric and humanized mAbs, were used. mAbs having the human Fc part of the IgG molecule were the most effective. The killing capacity of PBMC as well as of granulocytes was statistically significantly enhanced when mAbs were added. M-CSF and GM-CSF were the best CSF for augmenting the lytic capacity of PBMC in ADCC. G-CSF had no significant effect on PBMC. Spontaneous cytolysis of PBMC was significantly augmented only by M-CSF. Granulocytes were, in general, significantly less effective than PBMC but may be equally effective ki...Continue Reading

References

Jan 1, 1978·Advances in Cancer Research·R B Herberman, H T Holden
Oct 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M G SandaM T Lotze
Oct 1, 1991·Immunology Today·G Vairo, J A Hamilton
Jan 1, 1990·International Journal of Cell Cloning·J D GriffinY Kanakura
Feb 1, 1989·The Journal of Clinical Investigation·J C Unkeless
Mar 15, 1989·Journal of the National Cancer Institute·D IliopoulosD Herlyn
Jan 1, 1968·Scandinavian Journal of Clinical and Laboratory Investigation·C E Mogensen
Jan 1, 1983·Scandinavian Journal of Haematology·C LindemalmR Sundblad
Mar 12, 1993·International Journal of Cancer. Journal International Du Cancer·P RagnhammarH Mellstedt
Jan 1, 1987·Immunology Today·T A Hamilton, D O Adams

❮ Previous
Next ❯

Citations

Jul 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E Schneider-Gädicke, G Riethmüller
Jun 26, 2003·The Surgical Clinics of North America·Ginard Henry, Warren L Garner
Jul 4, 1998·International Journal of Radiation Oncology, Biology, Physics·A RovirosaA Biete
Oct 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M HejnaC C Zielinski
Apr 4, 2003·The International Journal of Biochemistry & Cell Biology·B KubistaM Micksche
May 31, 2012·Immunotherapy·Holbrook E KohrtJoshua Brody
Jul 1, 1996·Critical Reviews in Oncology/hematology·C Denzlinger
May 11, 2010·Expert Review of Vaccines·Kevin S CliveGeorge E Peoples
Apr 23, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guillaume CartronJean-Francois Rossi
Jul 31, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·N M IsbelR C Atkins
Sep 11, 2003·Molecular & Cellular Proteomics : MCP·Yee-Guide Yeung, E Richard Stanley
Dec 22, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Katharina NemethClaudia Goettsch
Jul 15, 1999·International Journal of Cancer. Journal International Du Cancer·I BergmanN K Cheung
Jul 10, 2008·Expert Opinion on Drug Metabolism & Toxicology·Xavier Thomas
Jan 1, 2021·Frontiers in Oncology·Jane KooAlisa B Lee-Sherick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.